Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae
Status:
Unknown status
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy in achieving clinical cure in non-bacteremic urinary tract
infections (UTI) caused by Escherichia coli or Klebsiella pneumoniae producers of
extended-spectrum β-lactamases (ESBL) in adult patients. Half of participants will receive
Piperacillin/Tazobactam as treatment, while the other half will receive Carbapenems.
The investigators will verify that Piperacillin/Tazobactam is not inferior in achieving
clinical cure, and that is not associated with a higher risk of adverse events in the
directed treatment of non-bacteremic UTI compared to Carbapenems.
The researchers hope to improve the use of antibiotics in the non-bacteremic UTI, reducing
the "collateral damage" related to a deterioration in the prognosis of patients and the
generation of resistant germs caused by the use of broad-spectrum antibiotics as carbapenems.
Phase:
Phase 4
Details
Lead Sponsor:
Universidad del Norte
Treatments:
Ertapenem Meropenem Piperacillin Piperacillin, Tazobactam Drug Combination Tazobactam